suspend coverag
reason report
multipl shot goal highlight long-term upsid potenti
bottom line initi coverag htgm share
outperform rate price target believ htgm
grow funnel biopharma partnership project current
potenti turn fda approv companion
recent trial failur biopharma partner project
may htgm multipl shot goal
project on-going incom project funnel still look strong
backdrop oncolog trial market
loss believ revenu like end lower end
full year guid base ruo research
use busi constitut sale continu
deliv long-term compound-annual-growth-rate readout year-
end potenti drive upsid
outlook lever pharma project cdx long-term
help broaden access htgm product htgm base ruo
busi remain solid grow compound-annual-growth-rate provid
foundat funnel lucr also highli binari cdx
conduct oncolog trial look diagnost partner
deliv cdx assay develop regulatori approv
htgm partnership deliv exclus
agreement deliv strong partner broad world-wide reach
stable/approv instrument platform htgm product
high sensit limit challeng tissu sampl
continu set htgm apart believ htgm continu
differenti rest tumor tissu diagnost offer
market given uniqu chemistri workflow deliv
higher sensit low sampl requir formalin-fix paraffin-
embed ffpe tissu sampl htgm use one micron tissu
slide obtain data compar slide need competitor
htgm chemistri also compat ion
base ruo busi continu deliv project funnel
stay strong believ htgm ruo project funnel continu
stay strong believ biopharma open collabor
creat partnership earli stage enhanc probabl
success cdx product htgm current earli stage project
mix biopharma hope increas number
project funnel continu grow though time remain unclear
believ averag believ project end
full-blown cdx project continu see growth veri/o lab
expect almost compound-annual-growth-rate ruo segment longer run
life scienc tool diagnost
dcf w/ beta lt growth rate
wacc
net debt total capit
compani inform leerink partner llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
bottom line initi coverag htgm share outperform rate
price target believ htgm grow funnel biopharma partnership
project current potenti turn fda approv companion
diagnost cdx long-term drive signific revenu upsid despit recent trial failur
biopharma partner project may htgm multipl shot goal
project on-going incom project funnel still look strong
backdrop oncolog trial market loss
believ revenu like end lower end full year guid
base ruo research use busi constitut sale continu
deliv long-term compound-annual-growth-rate readout year-end potenti
drive upsid
outlook lever pharma project cdx long-term help broaden
access htgm product htgm base ruo busi remain solid grow
compound-annual-growth-rate provid foundat funnel lucr also highli binari cdx
increasingli look diagnost partner deliv cdx assay
develop regulatori approv htgm support partnership
deliv exclus agreement deliv strong partner broad world-wide
reach stable/approv instrument platform htgm product
high sensit limit challeng tissu sampl continu set htgm apart
believ htgm continu differenti rest tumor tissu diagnost
offer market given uniqu chemistri workflow deliv higher sensit
low sampl requir ffpe tissu sampl htgm use one micron tissu slide
obtain data compar slide need competitor htgm chemistri also
compat ion torrent sequenc
base ruo busi continu deliv project funnel stay strong believ
htgm ruo project funnel continu stay strong believ biopharma open
collabor creat partnership earli stage enhanc probabl
success cdx product htgm current earli stage project mix biopharma
hope increas number project funnel continu grow though time
remain unclear believ averag project end full-blown cdx
project continu see growth veri/o lab expect compound-annual-growth-rate ruo
segment longer run
project funnel drive solid research ruo revenu long-term success
depend companion diagnost opportun
htgm grow funnel biopharma collabor clinic trial project
potenti turn success fda approv companion diagnost cdx long-term drive
signific revenu upsid base ruo research use busi constitut
sale continu strong expect deliv long-term compound-annual-growth-rate
even higher oncolog trial conduct need
technolog assay deliv data limit sampl larg panel remain
high believ htgm continu get seat biopharma partnership tabl major
oncolog trial look cdx product current htgm project
funnel pharma project work variou stage
develop cdx
htgm technolog enabl detect quantif challeng sampl low amount
and/or poor qualiti accur high sensit htgm chemistri instrument
enabl nucleic acid extraction-fre highli effici fast prepar genom librari
downstream analysi superior reliabl reproduc sensit edgeseq assay
panel analyt valid sampl input rang mm mm tumor surfac
area singl section allow comprehens molecular profil either larg
surgic resect small needl core biopsi technolog suit autom
facilit process wide varieti sampl includ challeng formalin-fix
paraffin-embed ffpe sampl sampl tissu volum scarc technolog
abil multiplex hundr thousand differ target singl reaction
elimin technic challeng step reduc hands-on time
believ despit recent trial failur biopharma partner project
may htgm still multipl shot goal project on-going
incom project funnel still look strong current though see failur
like drive revenu toward lower end full year guid
base ruo research use busi constitut sale continu
deliv long-term compound-annual-growth-rate though time remain unclear believ
averag project end full-blown cdx project continu see
growth veri/o lab expect almost compound-annual-growth-rate ruo segment longer run
market opportun htgm products/servic larg view
ngs-base technolog posit replac consolid exist test
mdx market base manag estim htgm custom includ biopharmaceut
compani academ research center molecular test laboratori primari
sourc revenu ruo profil target research custom pdp
collabor develop servic biopharmaceut compani respect ruo profil
revenu includ sale instrument relat assay kit payment profil
servic veri/o laboratori collabor develop revenu come assay
servic use primarili larg biopharmaceut compani
move toward person medicin pharma know need molecularli profil
patient oncolog trial develop cdx use therapi select
outsourc biomark discoveri develop cdx assay becom
success htgm larg depend upon growth oncolog market pharma
cdx believ market continu grow htgm continu
seat pharma tabl global cancer profil market clinic research/
translat accord estim compani report tissu liquid
tumor profil market expect grow compound-annual-growth-rate age
popul rise util biomark increas demand growth
htgm partnership biopharma cta/cdx assay develop
present upsid long-term
htgm current busi model leverag veri/o laboratori servic potenti per
project/program aggreg revenu current project htgm expect funnel
ruo project pharma cta/cdx assay develop partnership
program typic aggreg revenu per project year htgm also
cta/cdx assay develop project collabor biopharma compani
fewer emerg ruo funnel hold promis becom cdx long-term
accompani drug receiv approv cdx test develop novel
test new target therapi new gene set explor custom-built
proprietari algorithm specif drug indic phase project partner htgm
competit advantag access specif sampl cohort drug target
hold algorithm develop submiss studi regulatori approv
process success lead cdx test total address market rang
accord compani expect clinic cdx assay product
quick technolog adopt upon drug approv revenu like doubl next
year current htgm pharma project head toward potenti cdx cdx
approv market yet
sinc enter market compani adapt chemistri
compat major instrument market includ op thermo op ion-torr
qiagen generead compani market proprietari ngs-compat
catalog panel translat research biomark discoveri potenti companion
diagnost includ alkplu assay immuno-oncolog panel oncolog biomark
panel dlbcl diffus larg b-cell lymphoma cell origin assay note approv
alkplu dlbcl assay present potenti upsid number compani
focus develop pipelin expect develop suit profil panel immuno-
oncolog pharma dx/cdx collabor biopharma compani
world-wide innov network win consortium also use edgeseq investig
combin three target therapi treatment non-smal cell lung cancer nsclc
figur htgm pdp biopharma segment suggest phase project remain
critic htgm success near-medium term
pdp program could exceed expect boost revenu past expect
valuat compani depend heavili upon success biopharma project
model use probability-adjust outcom program outcom uncertain
multipl variabl play includ time magnitud signific
trial outcom overal believ program like posit appli high
probabl success program
novel panel boost ruo busi near-medium term
compani evolv laboratori servic provid total solut provid
instrument reagent molecular profil servic plan provid easi ngs-enabl
molecular profil assay servic wider audienc clinic lab us eu
htgm plan launch new kit expect grow ruo busi faster
well near-medium term htgm still deriv major revenu
custom research institut pharmaceut compani
htgm see signific tailwind recent decis
ncd -fda dual track pathway coverag relat cdx
follow parallel review fda grant approv foundationon cdx
test nov center medicar medicaid servic final
coverag test ensur better access cancer patient march also
cover fda-approv clear cdx use manag cancer believ htgm
benefit grow demand research diagnost set leverag
high sensit dynam rang instrument posit solut
enabl util simplifi workflow collabor cro partner
htgm enabl dissemin broader clinic commun recent ncd
creat payor advantag us fda approv cdx
larg genom molecular profil market opportun alreadi realiz
signific room grow increasingli therapi come market
tissu base tumor profil market larg estim current
market segment two categori clinic research market broadli
hereditari somat somat larger portion clinic market account
major advanc incorpor assay routin oncolog practic
tumor profil increasingli becom import therapi select therapi manag
among advanc stage cancer patient one promis applic molecular
profil target sequenc rna dna patient sampl order identifi
gene express pattern molecular marker diseas aid diagnosi gaug patient
prognosi predict respons avail therapi applic continu drive
fundament shift toward person medicin patient molecular profil use
guid treatment increas immuno-therapi drug see growth cdx
combin therapi gene express classif expect import
increas recognit go play broader role long-term
profil cancer select appropri therapi essenti underscor need
develop suitabl companion diagnost mani alreadi reach market
oncolog genom profil market driven increas preval cancer evolut
novel biomark grow interest person medicin enhanc treatment
differ tumor profil among earlier person treatment approach seen
hormon therapi breast cancer patient whose tumor express estrogen receptor
led trastuzumab treat patient breast cancer paradigm
shift led significantli improv patient outcom compar non-specif
chemotherapeut approach use past last decad signific effort
made non-smal cell lung cancer nsclc nsclc patient first profil egfr gene
mutat select patient like respond drug erlotinib came test
gene rearrang indic respons drug crizotinib addit
mutat rearrang includ ret kra other includ
nccn guidelin treatment lung cancer use guid patient
treatment expect increas develop biomark exist combo therapi
new therapi drive develop uptak cdx long-term
alreadi number assay compani realiz success market one
exampl fda approv companion diagnost wide use howev
base limit inform provid though pd-
immunohistochemistri base test believ base panel potenti product
featur tumor mutat burden tmb continu incorpor larger
panel provid greater insight long-term fmi nr also receiv ncd-fda approv
companion diagnost test foundat one broaden appeal molecular profil
pave pathway next set ncd-fda decis follow
number compani current compet tumor profil market includ limit
foundat medicin acquir roch roch abbott mp agil op
nanostr genom health liquid
biopsi compani well advanc genom led abil move panel
test character one biomark time analyz larg number
biomark genom profil allow target sequenc rna dna sampl
identifi gene express pattern molecular marker diseas help improv patient
diagnosi evalu diseas prognosi identifi optim therapeut regimen
increas role person medicin clinic applic molecular profil
includ clinic biomark develop patient stratif clinic trial companion
diagnost genom profil clinic research set use develop
molecular understand drug effect among variou patient group variabl gene
express could account failur rate among oncolog therapeut result
see increas role genom profil cdx overal hold potenti
drive therapi select agent target specif patient popul
clinic trial underway oncolog major drug develop
pharmaceut compani believ person target therapi develop
import futur success drug develop primari object drug-
develop effort improv respons rate payor also pressur lower patient treatment
cost play import role result biopharmaceut compani focus
develop biomark strategi increas rate patient respons new drug
develop gener studi focu varieti biolog profil marker includ
rna protein express level and/or presenc absenc dna mutat gene
fusion rearrang detect genom dna express rna
htgm plan deliv novel rna-bas gene classifi help biopharma lead
academ institut better understand predict durabl respons immunotherapi
drug htgm long-term also plan develop novel dna profil test provid
inform mutat load microsatellit instabl genet factor
believ associ respons io inhibitor therapi htgm signific
competitor alreadi somewhat crowd field offer significantli valu biopharma
continu get seat tabl longer-run htgm expect turn stage
project stage final fda approv htgm see
biopharma project long-term succeed receiv fda approv
challeng tissu analysi
tissu molecular profil conduct multipl method clinic set current
includ immunohistochemistri fluoresc situ hybrid fish polymeras chain
reaction pcr gene express array gea next-gener sequenc despit
signific improv autom reduct cog current molecular profil
techniqu still remain complex requir capital-intens workflow rapidli scalabl
econom convert local laboratori
test perform cancer patient increas awar scarciti
tissu especi come small sampl needl biopsi limit tissu
extract led increas liquid biopsi base approach order identifi
key mutat resid select cell tissu tissu biopsi remain essenti gold
standard still certain indic lung liver physician limit amount
tissu biopsi skin biopsi perform physician offic wherea
invas procedur may need done hospit set indic harder
biopsi may abl produc small amount tissu analyz
challeng downstream analysi histor slide consum complet
diagnost workup tumor advent new molecular techniqu drive
addit demand tissu molecular test market today requir slide
smaller biopsi fail deliv enough sampl meet profil requir genom
test gener push area liquid biopsi enhanc
analysi smaller sampl htg molecular compet market front liquid
biopsi smaller sampl size pharma seek novel biomark combo therapi
new drug
tumor typic profil multipl molecular characterist gener mean
tissu would requir thu obtain maximum data limit tissu sampl
remain key htgm excel competit tissu requir
significantli less compar assay technolog market htgm work
micro um tissu slice still get meaning data tissu surpass level
sensit compet platform obtain ffpe sampl
htgm technolog perform sampl analysi limit amount sampl
ffpe fresh tissu gener htgm requir um micron tissu sampl
perform analysi significantli advantag tradit method view
requir tissu thu sensit htgm htgm focus
rna mrna mirna compar compet technolog might look dna
take time obtain tissu ship laboratori analyz turnaround
time vari week depend lab assay involv sampl go
pathologist review dna extract quantif librari prepar pool
hybrid captur librari qc sequenc read align mutat detect
data develop clinic report analyz htgm perform analysi
workflow return result within week
compani htg edgeseq system workflow decreas turnaround time convent
target rna seq workflow hour hour compet turnaround time
creat competit advantag htgm compet turnaround time alon may
enough captur signific market share competitor superior
favor test technolog believ htg abil detect high qualiti data small
amount sampl combin faster turnaround time help get project
funnel bode well multipl shot goal revenu growth long-term
figur workflow molecular profil clinic sampl use target
highlight turnaround time week ideal condit
figur htgm workflow vs tradit rna seq workflow turn-around time
beyond tissu workflow htgm also develop liquid biopsi assay advanc
cancer patient microbiolog see public htgm liquid biopsi field
focus profil circul mirna collect plasma/serum tumor identif
bacteri detect
scarc tissu avail could challeng open liquid biopsi opportun
believ could larger long-term believ faster turnaround time
significantli easier sampl avail help drive adopt liquid biopsi test despit
tissu gold standard still major case oncologist test
patient diagnos advanc stage iiib/iv squamou non-smal cell lung cancer nsclc
gene mutat rearrang inform first line therapi place liquid biopsi could
potenti use case test primarili due insuffici tissu evalu
patient
htgm liquid biopsi strategi fairli broad target mrna mirna molecul circul
compon cell-fre rna circul lymphocyt exosom fac sort
circul tumor cell collect plasma/serum blood cerebrospin fluid csf
figur type htgm liquid biopsi applic
htg molecular incorpor htgm commerci stage growth compani develop
market product servic enabl effici molecular profil htgm core compet
proprietari ngs-compat chemistri enabl nucleic acid extraction-fre highli
effici fast prepar genom librari sequenc challeng sampl
superior reliabl reproduc sensit compani found octob
headquart tucson az
compani oper three distinct line busi research use ruo precis
diagnost partnership pdp companion diagnost cdx stabl driver
revenu ruo revenu stream lever increas volum sampl expect
process
pdp contribut significantli revenu earlier year model due limit
visibl forecast project yet establish cdx busi could flourish
longer term biopharma program eventu materi therapi hard place
undu weight area well breakdown histor project revenu
figur expect revenu segment type htgm
htgm pdp busi serv biopharma compani need develop companion
diagnost cdx pdp revenu compris cost recoveri milestone-bas revenu
earn develop assay biopharmaceut compani pdp project
budget biopharma compani total revenu share
htgm typic bring htgm revenu per deal
htgm current three pdp program pharma pharma pharma
pharma alreadi halt compani disclos drug studi
exact indic requir agreement htgm biopharma compani
differ indic come differ risk profil hard quantifi risk without know
drug indic competit landscap potenti drug therapeut area vari
probabl success pharmaceut agent differ materi one anoth
furthermor trial design also disclos critic regulatori approv trial
design differ phase phase compani chang drug profil point
develop import investor recogn unpredict natur project
result probabl weight outcom pharma project
expect revenu pdp project lumpi uncertain
compani expect funnel phase project biopharma ruo clinic trial
assay cta project partnership year cta/cdx assay
develop project drug/drug indic enter phase requir cta level design
valid typic spread across four stage stage assay develop stage clinic
trial stage regulatori submiss stage commerci two year
figur htgm pdp biopharma segment suggest phase project remain
critic htgm success near-medium term
june htgm enter agreement develop potenti
commerci ngs-base companion diagnost assay part project agreement
biopharma companythi project refer pharma one htgm
complet develop activ pharma one project develop phase
drug fail meet primari endpoint pharma one termin may
model project develop effort shelv
import keep mind pharma one project constitut signific part htgm
potenti upsid project halt believ htgm like deliv
lower end full year guid
octob bristol myer enter second research collabor
multipl indic current stage project complet stage
process expect complet cta util across multipl trial cohort
establish possibl phase trial opportun time-frame phase decis
point yet believ help drive potenti upsid project
could move regulatori submiss expect htgm share react posit trial
readout bmi associ trial outcom posit
januari htgm enter third agreement relat develop
activ ngs-base clinical-tri assay accord manag pharma-
project high volum categori schedul stage novemb
stage complet success program expect turn subsequ assay
develop activ potenti commerci companion diagnost assay
correspond drug htgm expect abl provid potenti indic market
opportun drug thu believ investor wait till either
htgm will disclos detail result drug cdx trial
htgm busi start ruo profil compani sell product instrument
consum servic veri/o lab biopharma academ medic center custom
compani expand clinic offer via partnership industri leader provid
molecular profil servic acceler product adopt ruo account htgm
revenu
instrument compani htg edgeseq sequenc close system
autom sampl prepar process use consum reagent panel
valid studi drug discoveri preclin studi clinic trial asp
edgeseq around averag gross margin around
instrument instal instrument revenu declin last four year
sharp drop larg driven shift toward veri/o lab
servic htgm perform test biopharma custom
consum expect account larger portion revenu begin
asp ruo kit vari product around per sampl us
eu averag gross margin
veri/o lab servic portion htgm busi provid servic custom
want access htgm technolog will commit purchas
instrument htgm engag biopharma compani ruo either sell
panel run test biopharma veri/o lab htgm provid
test servic price us eu veri/o lab
current largest portion htgm busi on-go project perform
segment appear solid view
ruo sale account signific portion htgm revenu
expect grow faster new kit launch schedul
growth ruo product revenu expect increas potenti higher
new instrument placement expect
compani third revenu stream dx/cdx revenu compani obtain ce
mark eu current appli clearanc via pre-market approv pma
pathway us two companion diagnost cdx assay specif target nucleic
acid biomark immuno-oncolog io util edgeseq system diagnost assay
htgm two dx product market europ alkplu assay
dlbcl cell origin assay compani also hand potenti
product develop evalu includ firali ra ivo breast
combin tam well
may htgm enter agreement firali allow firali develop
commerci theranost test predict rheumatoid arthriti ra patient respons
primari therapi million ra patient firali gene express signatur biopr
commerci htg edgeseq platform
htgm also develop alkplu assay first clinic diagnost test market
alkplu assay larg comprehens panel lung gene rearrang detect
certain fusion follow gene ret also insert
assay receiv ce mark europ march expect obtain fda pre-market
approv alkplu assay intend use alkplu assay
approv fda companion diagnost crizotinib therapi posit
nsclc case inform ret gene rearrang also
includ alkplu assay
longer run htgm look penetr cdx/mdx market us current
stand estim market today domin foundat medicin recent
acquir roch assay offer follow other includ
servic provid roch guardant cari life scienc name believ
custom market valu high sensit fast tat autom workflow low cost
assay believ htgm highli sensit lower-cost test lead cost effect
highli autom assay routin companion diagnost longer term new test
assay develop collabor research develop custom
believ becom key drive growth broader routin dx/cdx market
believ key differenti htgm technolog multiplex hundr
thousand biomark varieti sampl includ low sampl input formalin-fix
paraffin-embed ffpe tissu low sampl input sampl amount scarc
translat research clinic trial develop companion diagnost believ
present uniqu window opportun htgm technolog continu funnel
ruo project pdp program develop new assay reach market come
hold key htgm success broad world-wide distribut level
servic platform capabl
believ critic htgm success three reason
world-wide distribut enterpris level servic dx lab
sign master collabor agreement pharma
full infrastructur co-develop program intellectu properti platform
content extens regulatori experi global market reach independ
compani focus exclus type technolog
generead platform continu grow among clinic lab provid
solid support htgm assay uptak long-term
believ provid enorm boost htgm assay
generead place htgm biopharma partner assur
htgm assay run world-wide clinic trial site eventu
assay approv cdx given htgm instal edgeseq
instrument biopharma partner like cautiou move forward htgm
stage develop
offer technolog isol prepar dna rna protein blood
liquid tissu plant materi assay technolog amplifi enrich
make biomolecul access analysi identifi genet inform
pathogen gene mutat tumor qgen industry-lead bioinformat
solut integr autom system pcr technolog
provid cost-effect molecular test workflow action insight
biopharma gain confid platform
deep relationship pharmaceut biotechnolog compani
drug discoveri translat research effort boost genom inform
bioinformat solut increasingli employ guid research diseas
differenti patient popul like respond particular therapi
built favor establish track record among pharmaceut
biotech compani look co-develop companion diagnost pair target
drug reason believ htgm continu reli partner
believ remain crucial compon htgm success htgm depend
continu collabor biopharma compani materi pdp
revenu also split partnership end biopharma
note like continu hold leverag htgm term contract
negoti given posit partnership current hold approxim
competit landscap move target htgm potenti competitor broad
includ essenti molecular platform multiplex molecular analysi sampl prep
solut analysi current direct competitor htgm includ central clia lab
offer pcr base technolog product market believ
follow base cdx offer process get foundat
scienc name
believ ultim fda approv one htgm cdx assay put concern
rest dont see competit space declin expect consolid
like occur among assay success cdx like acquir tumor
profil offer solidifi next year technolog matur clinic evid
tumor profil continu build
htgm possess competit advantag fast turnaround time high multiplex
capabl lysi only/no extract protocol low sampl requir mani htgm
competitor foundat highli capit and/or
exist longer period enjoy sever competit advantag signific
brand recognit biopharma custom like lean toward partner well
capit execut broader product larger sale forc support personnel
support grow product competitor also larger establish
custom relationship fmi collect signific patient data
enabl improv tumor profil overal product also believ establish
competitor better access archiv patient sampl htgm secur access
archiv patient sampl includ ffpe tissu plasma serum whole blood preserv pax-
gene variou cytolog prepar togeth inform pertain clinic
outcom patient
htgm strong ip posit relat technolog employ htg edg htg edgeseq
platform assay htgm patent portfolio includ patent famili consist issu
 patent grant foreign patent patent applic pend unit state
foreign jurisdict htg edgeseq method patent expir april april
htgm also receiv japan patent nucleas protect method detect
nucleotid variant japan patent provid protect june given broad
deep ip portfolio htgm remain confid abl defend ip
htgm provid multipl avenu sell product core htgm assay approv
cdx ldt built upon chemistri remain key success long-term
broadli speak htgm edgeseq platform consist instrument consum
softwar analyt platform built htgm extraction-fre edgeseq chemistri
appli technolog call quantit nucleas protect qnpa offer simpler
effici workflow molecular profil htgm launch htg edgeseq system june
research clinic translat laboratori
figur htgm deploy qnpa chemistri multipl format
htgm chemistri remain heart technolog evolv overtim compat
multipl sequenc includ tmo ion torrent recent
generead htgm core extraction-fre qnpa chemistri modifi ad
tags/barcod sequenc adapt make librari compat
platform qnpa chemistri uniqu elimin need rna extract cdna
synthesi rna amplif rna-label step profil ten thousand mrna
microrna gene challeng sampl sampl includ small size
volum and/or low qualiti
htg chemistri conduct multipl step sampl sequenc
system first dna nucleas protect probe use bind target-specif region
two univers wing sequenc hybrid target rna hybrid
univers dna wingmen probe wing prevent digest nucleas
nucleas simpli enzym help cut dna specif point
nucleas digest single-strand nucleic acid includ unbound protect probe
rna nucleas digest occur remain hybrid dna protect probe form
hybrid complex roughli ratio dna protect probe rna target
hybrid complex go chemic reaction known alkalin hydrolysi releas
dna protect probe label sequenc adaptor tag
thermocycl thermocycl noth devic use heat cool dna/rna sampl
process amplifi strand essenti step introduc sampl
sequenc
dna protect probe final sequenc use standard instrument gener
report htg softwar open sourc softwar htg edgeseq assay current
avail process sampl batch rang
figur htgm chemistri dna protect probe hybrid
htgm chemistri follow key advantag
highli sensit low sampl volum requir key htgm assay lie
sensit edgeseq assay panel analyt valid sampl input rang
tumor surfac area singl section allow comprehens
molecular profil either larg surgic resect small needl core biopsi needl
core biopsi might avail sampl profil certain tumor type
higher level multiplex multiplex singl reaction challeng due
complex interact htgm edgeseq chemistri panel profil gene
one sampl potenti high level multiplex significantli reduc
amount tissu requir per sampl
rna extraction-fre rna gener isol purifi compon found
sampl lead time-consum process target loss bia test outcom htgm
chemistri allow rna extract ffpe sampl sampl improv sampl
util simplifi workflow reduc overal cost
cdna synthesi qrt-pcr tradit rna sequenc requir revers transcript
convert rna dna analysi process requir enzym move along extract
rna creat dna copi molecul damag fragment rna use
small rna strand becom difficult convert dna accur reproduc htgm
chemistri requir challeng rna-to-dna convers step
short protect probe mani sampl contain degrad rna due heat age poor
process and/or fixat caus damag fragment rna smaller strand htgm
chemistri use short protect probe base less suppos effici
longer strand rna quantit
simplic htgm chemistri fewer step compar rt-qpcr requir
extract cdna synthesi compar tradit rna sequenc htgm chemistri
need rna extract cdna synthesi shear rrna deplet ligat adenyl size
select reduc opportun bia amplif sampl degrad oper error
figur htgm platform involv multipl step perform
leverag dynam rang sensit htg chemistri sequenc
htgm dna probe librari compar refer databas consist sequenc
probe use assay nucleotid dna probe librari sequenc
store singl read platform platform capabl number
million read singl sequenc detect rare sequenc accur count
rel number abund sequenc reliabl accur measur differenti
express high low abund gene critic develop
valid gene express assay
htgm chemistri compat instrument platform
htgm chemistri compat platform includ generead
hiseq nextseq novaseq platform tmo ion torrent system
despit assay work across major sequenc platform htgm util
htgm workflow gene express profil also htgm workflow sampl prepar
molecular profil report accomplish approxim hour sampl
platform offer speed flexibl sensit accuraci low sampl requir allow
research profil thousand gene per sampl htgm place total instrument
number oper core research lab well medic center core lab
process sampl littl around per sampl
htg system consist htg instrument consum htgm platform perform
librari prepar data analysi path final result remain similar
sequenc rel littl time requir technician prepar sampl
htgm workflow take hour total hands-on time low hour compar
exist workflow consist follow modul sampl prepar
edgeseq assay kit hr includ hands-on time librari prepar target
pcr primer includ hands-on time quantit normal
includ hands-on time dna sequenc compat instrument
includ hands-on time data pars minut includ hands-
time flexibl provid htgm workflow allow custom optim use
platform base specif throughput workflow applic requir comparison
tradit rna sequenc also refer rnaseq fewer step requir molecular
figur htgm edgeseq platform workflow compar tradit workflow
valid equival quantit express result larg small sampl
volum htgm platform provid benefit gener quantit reproduc
accur profil result thousand gene singl setup small sampl requir
edgeseq assay panel analyt valid sampl input rang
tumor surfac area singl section allow comprehens molecular
profil either larg surgic resect small needl core biopsi needl core
biopsi might avail sampl profil certain tumor type intern studi
perform htgm resect versu core needl biopsi non-smal cell
lung cancer right panel correl transform count result correl
greater indic result two sampl size test htgm assay
figur htg edgeseq use smaller amount tissu avail surgic resect
versu core needl biopsi deliv result highlight sensit
platform small sampl requir gener ident data
gener reproduc quantit profil result limit sampl believ critic
custom htgm demonstr reliabl result fraction input rna ng
typic requir technolog studi mrna express level
obtain dilut seri ng ng rna measur
comparison dilut present high reproduc lowest correl
indic nearli ident molecular profil result dilut seri
figur htgm edgeseq demonstr capabl deliv consist molecular
profil wide rang sampl input
htgm chemistri address poor fidel non-fix ffpe tissu poor
fidel compar result across variou process condit one
greatest challeng molecular profil formalin fix sampl poor fidel
formalin fix sampl ffpe non-fix tissu report
fixat process lead high variabl sub-optim result molecular profil htgm
chemistri address poor fidel non-fix ffpe tissu give custom
accur assess ffpe tissu sampl
figur high fidel seen frozen ffpe tissu collect
breast cancer tumor sampl profil use htgm edgeseq immuno-oncolog assay
correl coeffici
compat multipl sampl type htgm platform also robust across mani biolog
sampl type handl sampl small larg tissu ffpe liquid cell cultur
make versatil detect target gene everi sampl htg chemistri handl
ffpe section ng extract rnn cell biofluid
figur htg edgeseq compat biolog sampl below-norm quantiti
detect gene fusion feasibl studi htg edgeseq chemistri demonstr
abil accur detect gene rearrang patient-deriv ffpe tissu use multipl
dna protect probe htg edgeseq system detect gene rearrang
fusion htgm develop assay allow gene fusion detect directli via
measur uniqu rna indirectli via measur ratio detect end
discrimin close relat sequenc htgm chemistri also provid high
specif enabl custom discrimin close relat sequenc shown
close relat synthet mirna pool profil npp probe bound off-
target sequenc differ signal-to-nois ratio greater
repeat reproduc repeat reproduc import consider
adopt platform high repeat demonstr profil
sampl technic replic use edgeseq immuno-oncolog assay fresh
frozen ffpe high reproduc demonstr profil
sampl profil three separ instrument across three day use edgeseq oncolog
instrument platform suitabl htgm assay
major platform includ ilmn sequenc thermo ion torrent platform
generead fulli compat htgm assay
platform high through-put sequenc employ
sequencing-by-synthesi sb chemistri sequenc entir human genom one
day system allow process one two flow cell simultan multipl sampl
molecularli barcod run togeth sequenc typic applic ilmn
sequenc includ small genom sequenc exom sequenc transcriptom analysi
year instrument becom workhors instrument use mani
diagnost lab well applic util exom platform current
market share world-wide mani order clinic translat
ion torrent platform use semiconductor chip help custom implement fast
simpl workflow commonli use system includ ion pgm person genom machin
sequenc platform provid versatil scalabl handl
multipl applic singl platform includ target sequenc exom sequenc
small rna mirna sequenc
believ generead platform suitabl platform given size gene panel
offer avail across world generead first
complet workflow system design perform whole next-gener sequenc
instrument reach placement sinc june launch
standard workflow consist follow major modul qiacub classic dna
purif librari prepar generead qiacub clonal amplif step librari
prepar generead instrument dna sequenc powerst data
analysi interpret traceabl generead platform perform sequenc
sequencing-by-synthesi sb detect fluoresc signal clonal amplifi
use qiacub generead workflow offer number benefit includ seamlessli
integr simpl effici workflow action insight interpret proven
gene panel bioinformat scalabl batch size sampl continu load
multipl flow cell highli reliabl result predict cost low initi
element generead workflow includ follow
nucleic acid extract success sequenc process reli highli qualiti
nucleic acid templat commonli use ffpe sampl artifact dna
level generead system workflow start nucleic acid extract step use
generead dna ffpe kit revers formalin artifact extract process fulli
autom provid standard sampl prepar
target enrich challeng find assay cover action variant
also compat lab sequenc workflow generead system offer menu
assay target variant differ cancer integr part generead
librari templat prepar librari prepar process involv multipl manual
step includ templat fragment end-repair amplif low-qual librari
prepar process result poor data generead templat prepar protocol fulli
autom minim sampl handl time amplif bia
sequenc generead platform use well-known sequencing-by-synthesi sb
method use stagger parallel load flow cell allow sequenc
run scalabl sequenc chemistri optim compat
data analysi interpret generead platform variant discoveri
bioinformat analysi autom qci analyz softwar go raw data
meaning result via bioinformat pipelin
htgm lot vet ventana roch
timothi tj johnson chief execut offic member board sinc
januari mr johnson serv presid htgm januari april
prior htgm mr johnson partner lvc consult april januari
mr johnson serv five year variou leadership role includ senior vice presid
global busi servic senior vice presid corpor develop oper
vice president/gener manag oper lean system ventana medic system
inc acquir roch hold inc prior ventana mr johnson
hillenbrand industri inc year serv numer role mr johnson
board director kalypto medic inc also previous serv industri co-chair
bioscienc leadership council southern arizona mr johnson attend indiana
univers earn busi
shaun mcmean senior vice presid financ administr chief
offic sinc februari prior htgm mr mcmean serv vice presid financ
securaplan technolog inc product suppli compani divis meggitt plc
aerospac defens energi conglomer may securaplan mr
mcmean financi consult partner tatum llc februari
tatum mr mcmean serv chief offic long compani full servic
residenti commerci real estat divis berkshir hathaway mr mcmean attend
pennsylvania state univers earn account
john lubniewski presid sinc april chief busi offic sinc april
prior htgm mr lubniewski serv variou leadership role ventana nine year
includ acquisit compani becom divis roch group global
headquart roch tissu diagnost rtd prior ventana mr lubniewski work
inc manufactur compani ten year mr lubniewski attend clarkson
univers earn chemic engin
rua jr senior vice presid regulatori affair qualiti system sinc
novemb prior htgm mr rua serv varieti qualiti regulatori role
increas respons recent ventana medic diagnost compani
member roch group global headquart rtd success led
initi pma approv clearanc multipl ivd companion diagnost test mr
rua also vice presid global regulatori clinic affair beckman coulter
 execut director qualiti regulatori third wave
inc third wave led regulatori clinic
strategi invad test invad hpv test mr rua receiv
microbiolog univers arizona
mike hrubiak senior vice presid molecular profil mdx sinc april
mr hrubiak serv seven year variou leadership role includ vice-president svp market
htgm prior htgm mr hrubiak serv senior market manag ventana medic
diagnost compani member roch group global headquart rtd prior
ventana mr hrubiak project manag rain bird corpor serv varieti
product role ge mr hrubiak receiv mechan engin univers
byron lawson senior vice presid biopharma partnership sinc jan mr
lawson serv close six year variou leadership role includ vice-president biopharma
partnership varieti role oper increas respons htgm prior
htgm mr lawson serv varieti role market sale oper inform
manag ventana medic diagnost compani member roch group
global headquart rtd
take averag comp analysi dcf price target
believ compani compar htgm small cap diagnost follow
tabl illustr current revenu multipl emerg small cap diagnost peer group
along htgm
dcf analysi use beta long-term growth rate wacc
arriv valuat expect continu growth beyond reach equilibrium
growth rate averag dcf comp method yield price target
primari risk htgm price target includ
success htgm pdp project depend heavili partnership
htgm repli qgen world-wide enterpris level franchis deep
relationship biopharma compani get pdp project contract believ
hold leverag htgm term project mileston profit share
contract negoti need develop panel htgm
contribut decid creat menu collabor
partner biopharma collabor see htgm pdp busi futur cdx
pipelin could greatli hamper
success htgm pdp project also depend greatli success
biopharma drug trial hard predict drug trial readout end
htgm stage pdp program good could happen time
depend drug indic pdp collabor project termin
depend contract like collabor gener
progress assay develop pdp project may acceler
forecast expect htgm receiv fda approv alkplu
launch new assay next coupl year ruo busi maintain
growth howev assay could receiv fda approv develop
new assay delay uptak new assay isnt good expect
rate ruo project pdp project high expect risk
estim profit htgm could delay
competitor could threaten chemistri multiplex low sampl input
requir extraction-fre sampl prep competitor launch panel
better sensit similar sampl volum requir could affect
htgm competit posit hamper adopt platform significantli
custom lack enthusiasm adopt htg edgeseq platform could still last despit
new assay launch htgm small sale forc adopt htgm
instrument slow past two year order acceler ruo product
adopt market educ effort must increas reach differ
research lab around world poor execut market sale strategi could
affect adopt
accret stock issuanc cost
accret prefer stock dividend
net incom loss attrib common stockhold
sg revenu
 revenu
oper expens sale
compani report leerink partner estim
cdx doubl
margin
kit
gm
